Drug-related information may refer to unlicensed products or uses that may not be approved in your country. Please consult your local prescribing information for advice.
Click here to receive Congress reports in RSS FormatFilter list using:
ESC 2010InCirculation.net Editor-in-Chief, Desmond Julian, and our Editorial Board are in Stockholm to lead our extended coverage of the sessions. We bring you News summaries and in-depth Special News Reports on all the major Hot Line and Clinical Trial Update sessions. In addition, our popular Video Highlights interviews will feature discussions between leading healthcare professionals, recorded on site.
With our Take-Home Messages and new Single-Slide Summaries condensing all the key data, you can dip in and out to find all that matters in a matter of moments!
ADA 2010InCirculation.net was in Orlando for the 70th Scientific Sessions of the American Diabetes Association. Among our coverage, we examine new data and revisit old data on pharmacotherapies for the treatment of type 2 diabetes, including important findings about canagliflozin and dapagliflozin, and continued follow-up from NAVIGATOR, BARI 2D and ACCORD.
Elsewhere, we focus on the important relationship between diabetes and cardiovascular disease.
WCC 2010Congress Reports from the WCC Scientific Sessions 2010, in Beijing, China, covering a broad range of topics related to the challenge of addressing cardiovascular disease on a global scale.
Among the coverage, we examine major clinical trials – TRITON TIMI-38, RE-LY and PLATO – from an Asian perspective, and the effect of income on epidemiology. Elsewhere, Valentin Fuster presents a fascinating discussion on the importance of promoting cardiovascular health in the developing world.
ACC.10The InCirculation.net Editorial Board members, writers, editors and cameramen were on site in Atlanta, GA to cover all the major developments during the 2010 American College of Cardiology Annual Scientific Sessions.
Among our Video Highlights interview, News Reports and Take-Home Messages were all the key Late-Breaking Clinical Trials: ACCORD, INVEST, NAVIGATOR, EVEREST II, RACE II, MM-WES, DOSE, ASPIRE and more – and our Special News Reports provide in-depth analysis from elsewhere at the conference.
